Dr. Davies joined the Naegis Board in 2011 and brings his leadership experience in the large pharmaceutical environment and his expertise in inflammatory mechanisms and pharmacology. He obtained his Ph.D. in 1967 at the Welsh National School of Medicine based on studies of the effects of aspirin and other salicylates on blood cells, including platelets. After a postdoctoral fellowship in the Department of Medicine at New York University School of Medicine, he returned to the UK in 1970 to the MRC Clinical Research Center where he was appointed a permanent member of the MRC staff based on his work on macrophage function. In 1975, he was recruited to Merck in Rahway, New Jersey, to establish research programs on novel mechanism anti-inflammatory drugs. Over the subsequent quarter of a century until his retirement in 2003 as Executive Director and Head, Immunology Research, he was involved in a broad range of research and development activities targeting immune and non-immune based inflammatory diseases. He has published over 130 peer reviewed manuscripts and is an inventor on a number of issued United States patents. Since 2003, he has been active as a consultant to numerous pharmaceutical companies and has become involved in the establishment of several new companies.